January 21, 2010 –
Intrinsic Bioprobes announced the exclusive licensing of two novel biomarkers for diabetes to
Ortho-Clinical Diagnostics, Inc. (Raritan, NJ). The biomarkers are modified forms of blood-circulating proteins and have been linked with the presence of pre-diabetes and type 2 diabetes. The financial terms of the licensing agreement were not disclosed.
“The biomarkers were discovered using Intrinsic Bioprobes’ unique Mass Spectrometric Immunoassay technologies”...
[PDF] Intrinsic Bioprobes' Press Release -
